Literature DB >> 1379143

Infectious disease therapy in the 1990s. Where are we heading?

M Rozenberg-Arska1, M R Visser.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1379143     DOI： 10.2165/00003495-199243050-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  66 in total

Review 1.  Detection of glycopeptide resistance in clinical isolates of gram-positive bacteria.

Authors:  N Woodford; A P Johnson; R C George
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

2.  Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma.

Authors:  R Badaro; E Falcoff; F S Badaro; E M Carvalho; D Pedral-Sampaio; A Barral; J S Carvalho; M Barral-Netto; M Brandely; L Silva
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

Review 3.  Monoclonal antibodies for treatment of gram-negative infections.

Authors:  L S Young; R Gascon; S Alam; L E Bermudez
Journal:  Rev Infect Dis       Date:  1989 Nov-Dec

Review 4.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

Review 5.  Amphotericin B nephrotoxicity.

Authors:  R Sabra; R A Branch
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 6.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

7.  Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynaecological origin.

Authors:  E Lachman; S B Pitsoe; S L Gaffin
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

Review 8.  Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients.

Authors:  B E Kreger; D E Craven; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

9.  Cytokine appearance in human endotoxemia and primate bacteremia.

Authors:  D G Hesse; K J Tracey; Y Fong; K R Manogue; M A Palladino; A Cerami; G T Shires; S F Lowry
Journal:  Surg Gynecol Obstet       Date:  1988-02

Review 10.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546
View more
  2 in total

1.  Pediatric infectious diseases: future campaigns.

Authors:  A Kumar; S Chaudhary
Journal:  Indian J Pediatr       Date:  1995 Jan-Feb       Impact factor: 1.967

2.  Tumor necrosis factor alpha (TNF-alpha) production in mice immunized with Escherichia coli: correlation with mortality after lethal challenge and production of a native inhibitor of TNF-alpha activity.

Authors:  G Raponi; N Keller; M Rozenberg-Arska; M T Lun; C Mancini; J Verhoef
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.